Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID L OLIVER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1164404455
CMS profile
623992
Location
OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$770.26

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $770.26 8

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $500.92 5
Bayer HealthCare Pharmaceuticals Inc. $249.09 2
Smith+Nephew, Inc. $20.25 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID L OLIVER

NPI 1164404455 · CMS profile ID 623992

Allopathic & Osteopathic Physicians / Family Medicine

OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164404455?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164404455?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164404455?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1164404455?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $770.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $118.7612/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885977761 CMS
Janssen Pharmaceuticals, Inc $118.6110/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885977767 CMS
Janssen Pharmaceuticals, Inc $124.4607/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885977757 CMS
Smith+Nephew, Inc. $20.2506/15/2022 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 960983941 CMS
Bayer HealthCare Pharmaceuticals Inc. $124.6306/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930083217 CMS
Bayer HealthCare Pharmaceuticals Inc. $124.4605/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930157679 CMS
Janssen Pharmaceuticals, Inc $17.1205/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885977773 CMS
Janssen Pharmaceuticals, Inc $121.9704/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885977751 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $405.23 5
PY2020 $282.42 6
PY2021 $509.12 6
PY2022 $770.26 8
PY2023 $290.27 6
PY2024 $2,305.91 23
PY2025 $352.28 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,288,478.03 35
PY2024 Recipient $48,730.50 2
PY2024 Principal investigator $760,191.54 106
PY2023 Recipient $795.01 2
PY2023 Principal investigator $798,688.88 48
PY2022 Recipient $274.00 1
PY2022 Principal investigator $738,187.49 166
PY2021 Principal investigator $437,882.52 38
PY2020 Recipient $193,202.48 6
PY2020 Principal investigator $298,634.23 42
PY2019 Principal investigator $211,648.73 76

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $1,703.73 12/17/2020 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728728315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,250.00 12/10/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724480995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $975.00 11/24/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724479635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $760.50 11/24/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724479637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.98 11/24/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724479639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,850.00 11/24/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724479641
Principal investigator 1 Eli Lilly and Company $1,388.57 11/19/2020 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728728673
Principal investigator 1 Eli Lilly and Company $1,507.68 11/19/2020 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 728728677
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $300.00 11/18/2020 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713694699
Recipient Eli Lilly and Company $50,100.00 11/17/2020 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 728717721
Recipient Eli Lilly and Company $50,310.00 11/17/2020 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS No dispute reported 06/30/2026 728718833
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,165.00 10/28/2020 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713694071
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,422.00 10/28/2020 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713694073
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,165.00 10/28/2020 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713694077
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $2,071.57 10/27/2020 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 728728679
Principal investigator 1 Eli Lilly and Company $1,923.90 10/27/2020 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS No dispute reported 06/30/2026 728728517
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,500.00 10/08/2020 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713691755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/08/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724476867
Principal investigator 1 Eli Lilly and Company $481.50 10/06/2020 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728743513
Recipient Eli Lilly and Company $92,222.98 09/21/2020 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728718830
Recipient Eli Lilly and Company $200.00 09/14/2020 Covered Recipient Physician EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) No dispute reported 06/30/2026 728718955
Recipient Eli Lilly and Company $50.00 08/31/2020 Covered Recipient Physician A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK No dispute reported 06/30/2026 728717725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,471.63 07/29/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724472623
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $5,679.00 07/13/2020 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713686215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $619.40 07/09/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724470051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,841.98 06/24/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724468769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $619.40 05/27/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724465565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,430.00 05/27/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724465569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $775.40 05/27/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724465575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,430.00 05/27/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724465579
Principal investigator 1 Eli Lilly and Company $883.03 05/14/2020 Non-covered Recipient Entity
RENSTAR INC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728739331
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,844.00 05/12/2020 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713683111
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,844.00 05/12/2020 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713683159
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,165.00 05/12/2020 Non-covered Recipient Entity
Renstar Medical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 713683255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,762.97 05/07/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724463251
Recipient Eli Lilly and Company $319.50 04/24/2020 Covered Recipient Physician RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 728719402
Principal investigator 1 Radius Health, Inc. $67.56 04/01/2020 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATIDE-SMTS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS No dispute reported 06/30/2026 745115791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.00 03/26/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724459201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,490.00 03/26/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724459205
Principal investigator 1 PFIZER INC. $111,269.70 03/13/2020 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 742972765
Principal investigator 1 Radius Health, Inc. $395.00 03/12/2020 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study To Evaluate The Efficacy And Safety Of Abaloparatide-smts For The Treatment Of Postmenopausal Women With Osteoporosis No dispute reported 06/30/2026 745115569
Principal investigator 1 Radius Health, Inc. $13,876.00 03/12/2020 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study To Evaluate The Efficacy And Safety Of Abaloparatide-smts For The Treatment Of Postmenopausal Women With Osteoporosis No dispute reported 06/30/2026 745115571
Principal investigator 1 Radius Health, Inc. $690.30 03/12/2020 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study To Evaluate The Efficacy And Safety Of Abaloparatide-smts For The Treatment Of Postmenopausal Women With Osteoporosis No dispute reported 06/30/2026 745115575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,893.07 03/12/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724457767
Principal investigator 1 PFIZER INC. $29,133.00 03/03/2020 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 742972771
Principal investigator 1 Radius Health, Inc. $16,477.74 02/27/2020 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study To Evaluate The Efficacy And Safety Of Abaloparatide-smts For The Treatment Of Postmenopausal Women With Osteoporosis No dispute reported 06/30/2026 745115565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42,102.62 01/28/2020 Non-covered Recipient Entity
RENSTAR INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724452993
Principal investigator 1 PFIZER INC. $125.00 01/14/2020 Non-covered Recipient Entity
RENSTAR LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 742972703